Beleaguered Zafgen crushed after FDA demands force it to dump lead drug
Stymied at the FDA with a lingering clinical hold on its lead obesity drug, Zafgen is dumping the therapy and retreating to a preclinical program in the pipeline.
The biotech announced after the market closed on Tuesday that it will now circle the wagons around ZGN-1061 after beloranib was linked with the death of two patients in a pivotal study. Zafgen also says it will once again reduce its ranks, chopping 34% of the survivors and cutting the payroll to 31. The reorganization is claiming the jobs of Patrick Loustau, president, and Alicia Secor, chief commercial officer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.